Slingshot members are tracking this event:
FDA Grants Orphan Drug Designation to Biomarin's BMN-270 for Hemophilia A
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Mar 01, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Orphan Drug Designation, Bmn-270, Fda, Hemophilia A